Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report released on Monday,RTT News reports. Wedbush currently has a $11.00 price target on the stock.

CATX has been the topic of several other reports. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Scotiabank started coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Finally, HC Wainwright started coverage on Perspective Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $14.56.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $2.36 on Monday. The firm has a fifty day moving average of $3.07 and a 200 day moving average of $6.99. Perspective Therapeutics has a one year low of $2.32 and a one year high of $19.05.

Institutional Trading of Perspective Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC raised its stake in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after acquiring an additional 355,685 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its position in Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after acquiring an additional 120,991 shares during the last quarter. Octagon Capital Advisors LP grew its holdings in shares of Perspective Therapeutics by 62.1% during the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the last quarter. Finally, State Street Corp increased its position in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.